{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:02:36Z","timestamp":1790650956879,"version":"4.1.0"},"reference-count":41,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sekisui Medical Co., Ltd."},{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Thymus- and activation-regulated chemokine (TARC, also known as CCL17) is used as a biomarker for atopic dermatitis. The methods currently used for its measurement are complex, time-consuming, and require large machinery, warranting the need for a method that is simple, has a quick turnaround time, and requires less complex machinery. We evaluated the analytical performance of a novel latex turbidimetric immunoassay method, \u201cNanopia TARC\u201d, on 174 residual serum samples from patients with skin or allergic diseases. This evaluation included the assessment of the limit of blank\/detection\/quantification (LOB\/D\/Q), precision, accuracy, linearity, interference, and commutability between Nanopia TARC and \u201cHISCL TARC\u201d, based on the chemiluminescent enzyme immunoassay (CLEIA) method. The LOB\/D\/Q values were 13, 57, and 141 pg\/mL, respectively. The coefficient of variation of the repeatability was 0.9\u20133.8%, and that of the intermediate precision was 2.1\u20135.4%. The total error of the accuracy was 1.9\u201313.4%. The linearity was 141 and 19,804 pg\/mL for TARC. The correlation coefficient between Nanopia TARC and HISCL TARC determined using the Passing\u2013Bablok regression analysis was 0.999. Furthermore, the concordance of diagnostic criteria with AD was 92%. Nanopia TARC was confirmed to have the same analytical performance for TARC measurement as the existing CLEIA method.<\/jats:p>","DOI":"10.3390\/diagnostics13182935","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T10:00:23Z","timestamp":1694685623000},"page":"2935","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analytical Performance of a Novel Latex Turbidimetric Immunoassay, \u201cNanopia TARC\u201d, for TARC\/CCL17 Measurement: A Retrospective Observational Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0049-0834","authenticated-orcid":false,"given":"Keita","family":"Yamashita","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Takebayashi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Hirai","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuka","family":"Mitsui","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Terada","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyasu","family":"Niizeki","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6090-0551","authenticated-orcid":false,"given":"Akira","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenya","family":"Ogitani","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Fujikawa","sequence":"additional","affiliation":[{"name":"Diagnostic Products Development, Department Research & Development, Sekisui Medical Co., Ltd., Tokyo 103-0027, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2868-0888","authenticated-orcid":false,"given":"Marie","family":"Komori","sequence":"additional","affiliation":[{"name":"Diagnostic Products Development, Department Research & Development, Sekisui Medical Co., Ltd., Tokyo 103-0027, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Diagnostic Products Development, Department Research & Development, Sekisui Medical Co., Ltd., Tokyo 103-0027, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimitsu","family":"Arai","sequence":"additional","affiliation":[{"name":"Diagnostic Products Development, Department Research & Development, Sekisui Medical Co., Ltd., Tokyo 103-0027, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-5324","authenticated-orcid":false,"given":"Masato","family":"Maekawa","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"21514","DOI":"10.1074\/jbc.271.35.21514","article-title":"Molecular Cloning of a Novel T cell-Directed CC Chemokine Expressed in Thymus by Signal Sequence Trap Using Epstein-Barr Virus Vector","volume":"271","author":"Imai","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nm.2760","article-title":"T cell Homing to Epithelial Barriers in Allergic Disease","volume":"18","author":"Islam","year":"2012","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00281-021-00857-w","article-title":"What Does Elevated TARC\/CCL17 Expression Tell Us About Eosinophilic Disorders?","volume":"43","author":"Catherine","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1067\/mai.2002.126378","article-title":"Plasma Concentration of Thymus and Activation-Regulated Chemokine is Elevated in Childhood Asthma","volume":"110","author":"Leung","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0002-9440(10)65424-7","article-title":"High Expression of the CC Chemokine TARC in Reed-Sternberg cells: A Possible Explanation for the Characteristic T-Cell Infiltrate in Hodgkin\u2019s Lymphoma","volume":"154","author":"Visser","year":"1999","journal-title":"Am. J. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/intimm\/dxu079","article-title":"CCR4 and its Ligands: From Bench to Bedside","volume":"27","author":"Yoshie","year":"2015","journal-title":"Int. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1067\/mjd.2003.132","article-title":"Thymus and Activation-Regulated Chemokine (TARC\/CCL17) in Mycosis Fungoides: Serum TARC Levels Reflect the Disease activity of Mycosis Fungoides","volume":"48","author":"Kakinuma","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kuzumi, A., Yoshizaki, A., Ebata, S., Fukasawa, T., Yoshizaki-Ogawa, A., Asano, Y., Oba, K., Sato, S., and Serum, T.A.R.C. (2021). Serum TARC Levels in Patients with Systemic Sclerosis: Clinical Association With Interstitial Lung Disease. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040660"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1002\/art.27678","article-title":"CCL17\/Thymus and Activation-Related Chemokine in Churg-Strauss Syndrome","volume":"62","author":"Dallos","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1067\/mai.2001.113237","article-title":"Thymus and Activation-Regulated Chemokine in Atopic Dermatitis: Serum Thymus and Activation-Regulated Chemokine Level is Closely Related With Disease Activity","volume":"107","author":"Kakinuma","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1398-9995.2005.00774.x","article-title":"Serum Thymus and Activation-Regulated Chemokine, Macrophage-Derived Chemokine and Eotaxin as Markers of Severity of Atopic Dermatitis","volume":"60","author":"Targowski","year":"2005","journal-title":"Allergy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1399-3038.2011.01225.x","article-title":"Serum TARC and CTACK Concentrations in Children With Atopic Dermatitis, Allergic Asthma, and Urticaria","volume":"23","author":"Machura","year":"2012","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jaad.2014.07.031","article-title":"Utility of Serum Thymus and Activation-Regulated Chemokine as a Biomarker for Monitoring of Atopic Dermatitis Severity","volume":"71","author":"Landheer","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/exd.12988","article-title":"The Crucial Role of IL-22 and Its Receptor in Thymus and Activation Regulated Chemokine Production and T-Cell Migration by House Dust Mite Extract","volume":"25","author":"Jang","year":"2016","journal-title":"Exp. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2022.11.023","article-title":"Skin TARC\/CCL17 Increase Precedes the Development of Childhood Atopic Dermatitis","volume":"151","author":"Halling","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_16","first-page":"240","article-title":"Reduction of Serum TARC Levels in Atopic Dermatitis by Topical Anti-Inflammatory Treatments","volume":"32","author":"Yasukochi","year":"2014","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"ref_17","first-page":"e315","article-title":"English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021","volume":"49","author":"Saeki","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/ng.2438","article-title":"Genome-Wide Association Study Identifies Eight New Susceptibility Loci for Atopic Dermatitis in the Japanese Population","volume":"44","author":"Hirota","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_19","first-page":"1","article-title":"Itch and Atopic Dermatitis: Clinical and Experimental Studies","volume":"165","author":"Wahlgren","year":"1991","journal-title":"Acta Derm. Venereol. Suppl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0091-6749(99)70536-1","article-title":"Worldwide Variations in the Prevalence of Symptoms of Atopic Eczema in the International Study of Asthma and Allergies in Childhood","volume":"103","author":"Williams","year":"1999","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ilic, I., Stojkovic, A., Velickovic, V., Zivanovic Macuzic, I., and Ilic, M. (2023). Atopic Dermatitis in Children Under 5: Prevalence Trends in Central, Eastern, and Western Europe. Children, 10.","DOI":"10.3390\/children10081275"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of Care For the Management of Atopic Dermatitis: Section 1. Diagnosis and Assessment of Atopic Dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","unstructured":"Clinical Laboratories Standards Institute (2014). Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline, Clinical and Laboratory Standards Institute. [3rd ed.]. CLSI Document ep05-A3."},{"key":"ref_24","unstructured":"Clinical Laboratories Standards Institute (2016). Evaluation of Total Analytical Error for Quantitative Medical Laboratory Measurement Procedures, Clinical and Laboratory Standards Institute. [2nd ed.]. CLSI Document ep21."},{"key":"ref_25","unstructured":"Clinical Laboratories Standards Institute (2016). Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures, Clinical and Laboratory Standards Institute. [2nd ed.]. CLSI Document ep17-A2."},{"key":"ref_26","unstructured":"Clinical Laboratories Standards Institute (2016). Evaluation of Linearity of Quantitative Measurement Procedures, Clinical and Laboratory Standards Institute. [2nd ed.]. CLSI Document ep06."},{"key":"ref_27","unstructured":"Clinical Laboratories Standards Institute (2018). Interference Testing in Clinical Chemistry, Clinical and Laboratory Standards Institute. [3rd ed.]. CLSI Document ep07."},{"key":"ref_28","unstructured":"Clinical Laboratories Standards Institute (2018). Measurement Procedure Comparison and Bias Estimation Using Patient Samples, Clinical and Laboratory Standards Institute. [3rd ed.]. CLSI Document ep09c."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"145145","DOI":"10.1016\/j.gene.2020.145145","article-title":"Serum CCL17 Level Becomes a Predictive Marker to Distinguish Between Mild\/Moderate and Severe\/Critical Disease in Patients With COVID-19","volume":"766","author":"Sugiyama","year":"2021","journal-title":"Gene"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.resinv.2022.12.006","article-title":"IFN-\u03bb3 and CCL17 as Predictors of Disease Progression in Patients With Mild to Moderate COVID-19: A Cohort Study in a Real-World Setting","volume":"61","author":"Sekimoto","year":"2023","journal-title":"Respir. Investig."},{"key":"ref_31","unstructured":"Westgard, Q.C. (2023, May 06). Desirable Specifications for Total Error, Imprecision, and Bias, Derived from Intra- and Inter-Individual Biologic Variation. Available online: http:\/\/www.westgard.com\/biodatabase1.htm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/1346-8138.12440","article-title":"Thymus and Activation-Regulated Chemokine as a Clinical Biomarker in Atopic Dermatitis","volume":"41","author":"Kataoka","year":"2014","journal-title":"J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in Atopic Dermatitis\u2014A Review on Behalf of the International Eczema Council","volume":"147","author":"Thyssen","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.flm.2017.06.006","article-title":"A Comparison Between China-Made Mindray BS-2000M Biochemical Analyzer and Roche cobas702 Automatic Biochemical Analyzer","volume":"1","author":"Chen","year":"2017","journal-title":"Front. Lab. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1515\/cclm-2014-1118","article-title":"Analytical Evaluation of Diazyme Procalcitonin (PCT) Latex-Enhanced Immunoturbidimetric Assay on Beckman Coulter AU5800","volume":"53","author":"Dipalo","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1515\/cclm-2020-0796","article-title":"Analytical Evaluation of Reebio Procalcitonin Latex-Enhanced Immunoturbidimetric Assay on the Hitachi Labospect 008AS","volume":"59","author":"Yuan","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jdermsci.2012.10.002","article-title":"Identification of Thymus and Activation-Regulated Chemokine (TARC\/CCL17) as a Potential Marker for Early Indication of Disease and Prediction of Disease Activity in Drug-Induced Hypersensitivity Syndrome (DIHS)\/Drug Rash With Eosinophilia and Systemic Symptoms (DRESS)","volume":"69","author":"Ogawa","year":"2013","journal-title":"J. Dermatol. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bjd.12948","article-title":"Elevated Serum Thymus and Activation-Regulated Chemokine (TARC\/CCL17) Relates to Reactivation of Human Herpesvirus 6 in Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)\/Drug-Induced Hypersensitivity Syndrome (DIHS)","volume":"171","author":"Ogawa","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.alit.2017.06.001","article-title":"The Thymus and Activation-Regulated Chemokine (TARC) Level in Serum at an Early Stage of a Drug Eruption is a Prognostic Biomarker of Severity of Systemic Inflammation","volume":"67","author":"Chinuki","year":"2018","journal-title":"Allergol. Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.alit.2016.06.003","article-title":"Serum TARC Levels are Strongly Correlated with Blood Eosinophil Count in Patients with Drug Eruptions","volume":"66","author":"Kaneko","year":"2017","journal-title":"Allergol. Int."},{"key":"ref_41","unstructured":"(2020). In Vitro Diagnostic Medical Devices-Requirements for Establishing Metrological Traceability of Values Assigned to Calibrators, Trueness Control Materials and Human Samples (Standard No. ISO 17511:2020)."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/18\/2935\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:50:13Z","timestamp":1760129413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/18\/2935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":41,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["diagnostics13182935"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics13182935","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]}}}